Pensionfund DSM Netherlands increased its position in shares of Anthem Inc (NYSE:ANTM) by 14.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,425 shares of the company’s stock after acquiring an additional 1,425 shares during the period. Pensionfund DSM Netherlands’ holdings in Anthem were worth $3,224,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Destination Wealth Management purchased a new stake in Anthem during the 1st quarter worth about $31,000. Lee Financial Co purchased a new stake in Anthem during the 1st quarter worth about $32,000. Liberty Wealth Management LLC purchased a new position in shares of Anthem in the 1st quarter valued at about $36,000. Cable Hill Partners LLC increased its holdings in shares of Anthem by 77.5% in the 1st quarter. Cable Hill Partners LLC now owns 126 shares of the company’s stock valued at $36,000 after acquiring an additional 55 shares during the last quarter. Finally, Executive Wealth Management LLC purchased a new position in shares of Anthem in the 1st quarter valued at about $46,000. 87.26% of the stock is currently owned by hedge funds and other institutional investors.
In other Anthem news, EVP Thomas C. Zielinski sold 8,826 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $283.92, for a total transaction of $2,505,877.92. Following the completion of the sale, the executive vice president now directly owns 33,183 shares of the company’s stock, valued at approximately $9,421,317.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Ronald W. Penczek sold 763 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $279.00, for a total value of $212,877.00. Following the sale, the senior vice president now directly owns 2,295 shares of the company’s stock, valued at $640,305. The disclosure for this sale can be found here. Insiders have sold a total of 11,245 shares of company stock worth $3,174,155 in the last 90 days. 0.17% of the stock is currently owned by company insiders.
NYSE:ANTM traded up $0.81 during mid-day trading on Tuesday, reaching $302.59. 969,266 shares of the stock were exchanged, compared to its average volume of 1,782,327. The company has a 50 day moving average of $288.94. The firm has a market capitalization of $77.62 billion, a PE ratio of 19.04, a P/E/G ratio of 1.12 and a beta of 0.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.61 and a quick ratio of 1.61. Anthem Inc has a 1 year low of $227.16 and a 1 year high of $317.99.
Anthem (NYSE:ANTM) last released its quarterly earnings results on Wednesday, April 24th. The company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.86 by $0.17. The firm had revenue of $24.39 billion for the quarter, compared to the consensus estimate of $24.31 billion. Anthem had a return on equity of 14.99% and a net margin of 4.23%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the business posted $5.41 EPS. Sell-side analysts expect that Anthem Inc will post 19.24 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 25th. Investors of record on Monday, June 10th were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, June 7th. This represents a $3.20 dividend on an annualized basis and a yield of 1.06%. Anthem’s dividend payout ratio is presently 20.14%.
ANTM has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price objective on shares of Emergent Biosolutions in a report on Sunday, April 21st. Barclays increased their price objective on T. Rowe Price Group from $90.00 to $95.00 and gave the company an “underweight” rating in a report on Thursday, April 25th. Zacks Investment Research downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. SunTrust Banks reiterated a “hold” rating and issued a $44.00 price objective on shares of Shutterstock in a report on Thursday, April 25th. Finally, Citigroup reiterated a “buy” rating on shares of Healthequity in a report on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $325.67.
Anthem, Inc, through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets.
Recommended Story: Initial Public Offering (IPO)
Want to see what other hedge funds are holding ANTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anthem Inc (NYSE:ANTM).
Receive News & Ratings for Anthem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem and related companies with MarketBeat.com's FREE daily email newsletter.